UNSPSC 51284307: Thiamphenicol glycinate hydrochloride

This classification denotes a protein synthesis inhibitor and antibiotic with the molecular formula C14H18Cl2N2O6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88VGC22BWE, chemically known as glycine, (2r,3r)-2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, hydrochloride (1:1), but more generally known as thiamphenicol glycinate hydrochloride, which bears US NIH Compound Identifier 197006.

European Medicines Agency schedules thiamphenicol glycinate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10970MIG. Most nations, for tariff purposes, schedule thiamphenicol glycinate hydrochloride under HS 29414000. SMILES: CS(=O)(=O)C1CCC(CC1)[C@H]([C@@H](COC(=O)CN)NC(=O)C(CL)CL)O.CL.

UNSPSC 51284307 Thiamphenicol glycinate hydrochloride is a Commodity code with minimal recent state and local procurement activity directly aligned to this specific pharmaceutical ingredient. The code nominally identifies a single active pharmaceutical substance, yet recent opportunities posted under this code do not specify thiamphenicol glycinate hydrochloride by name or formulation. Instead, the recent solicitations span broader medical supply categories — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and emergency medical consumables — that fall outside the narrow scope of a single chemical compound. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). Issuing bodies and procurement instruments vary widely: Seminole County issued an IFB for annual naloxone and drug deactivation system purchases; Texas HHS posted an RFI to explore direct-to-manufacturer pharmacy initiatives; the City of Tampa solicited sealed bids for emergency medical supplies; and MMCAP issued an RFP for generic pharmaceutical and OTC product framework agreements across multiple participating states.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with no clear concentration in any single region or state. Representative recent opportunities include the Seminole County IFB (IFB60459723LAS), due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a two-year initial term and one-year renewal option; the City of Tampa IFB (26P00145), due March 13, 2026, for 169 line items of emergency medical and first aid supplies to the Tampa Fire Department Rescue Division, designated a sheltered-market opportunity for certified Small Local Business Enterprises with an estimated contract value of $700,000; and the MMCAP RFP (S1070000015802), due March 26, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers across participating state and local government facilities. The code shows little relevant recent activity, and the mismatch between the nominal scope (a single active pharmaceutical ingredient) and the actual work being solicited (broader medical supply procurement, naloxone programs, and generic drug frameworks) suggests this code may be misapplied by issuing bodies or that state and local demand for thiamphenicol glycinate hydrochloride specifically does not translate into measurable recent solicitation activity.